https://aktiv8.io/news/ntqpe5c/an2-therapeutics-receives-u-s-fda-ind-clearance-to-proceed-with-planned-phase-2-global-stu 2026-11-02 never 0.6 https://aktiv8.io/news/nnkmeeb/inventisbio-announces-topline-results-of-a-phase-iii-study-of-nomelcitinib-tyk2-inhibitor- 2026-11-02 never 0.6 https://aktiv8.io/news/n10wjqoe/nutrition-biotech-publishes-bulk-nmn-powder-buyer-guide-to-2025-fda-records-documentation- 2026-11-02 never 0.6 https://aktiv8.io/news/n1746fch/stat-fda-oks-generic-hiv-prevention-shot-widening-access-for-lower-income-countries 2026-11-02 never 0.6 https://aktiv8.io/news/no4esvr/vicapsys-life-sciences-provides-shareholder-update-on-vicapsyn-tm-program-advancing-toward 2026-11-02 never 0.6 https://aktiv8.io/news/n14k1699/topgolf-tmrw-sports-partner-to-bring-tgl-wtgl-experiences-to-golf-fans-worldwide-ahead-of- 2026-11-02 never 0.6 https://aktiv8.io/news/n1joqmlb/teva-to-discontinue-phase-2-topas-msa-study-of-emrusolmin-tev-286-following-interim-futili 2026-11-02 never 0.6 https://aktiv8.io/news/n1591kxh/roche-receives-fda-510-k-clearance-for-new-cobas-eplex-respiratory-pathogen-panel-3-enabli 2026-11-02 never 0.6 https://aktiv8.io/news/n1rgo1eq/urogen-announces-first-patient-dosed-in-phase-1-trial-of-ugn-501-an-investigational-next-g 2026-11-02 never 0.6 https://aktiv8.io/news/ne965ps/sofinnova-partners-promotes-javier-nunez-vicandi-to-partner-strengthening-its-digital-medi 2026-11-02 never 0.6 https://aktiv8.io/news/n9ytoh1/stat-coming-readout-of-kymera-eczema-trial-is-a-high-stakes-moment-in-a-bid-to-rival-dupix 2026-11-02 never 0.6 https://aktiv8.io/news/n1p9y6zq/massive-bio-and-global-leadership-in-oncology-wellness-glow-announce-partnership-to-expand 2026-11-02 never 0.6 https://aktiv8.io/news/n1dqbjsq/lupin-receives-u-s-fda-approval-for-amifampridine-tablets 2026-11-02 never 0.6 https://aktiv8.io/news/nusq69t/biopharma-rethinks-globalization-as-geopolitical-risk-reshapes-supply-chains-and-partnersh 2026-11-02 never 0.6 https://aktiv8.io/news/nbt78p9/an2-therapeutics-receives-u-s-fda-ind-clearance-to-proceed-with-planned-phase-2-global-stu 2026-11-02 never 0.6 https://aktiv8.io/news/n18n1zt0/china-s-inventisbio-delivers-competitive-tyk2-data-in-phase-3-psoriasis-win 2026-11-02 never 0.6 https://aktiv8.io/news/nm2nvbr/nuvation-bio-to-present-additional-updated-phase-2-results-at-2026-society-for-neuro-oncol 2026-11-02 never 0.6 https://aktiv8.io/news/n10g4qx/pretzel-gains-uk-approval-for-px578-trial-to-treat-mitochondrial-disorder 2026-11-02 never 0.6 https://aktiv8.io/news/n13fydoc/monopar-to-present-at-aasld-the-liver-meeting-2026-phase-3-focus-baseline-data-and-alxn184 2026-11-02 never 0.6 https://aktiv8.io/news/nakc3sf/nmg-reaches-a-major-regulatory-milestone-with-the-granting-of-the-mining-lease-by-quebec-s 2026-11-02 never 0.6 https://aktiv8.io/news/nuh42b7/nuvation-bio-to-present-additional-updated-phase-2-results-at-2026-society-for-neuro-oncol 2026-11-02 never 0.6 https://aktiv8.io/news/n4qums7/massive-bio-and-global-leadership-in-oncology-wellness-glow-announce-partnership-to-expand 2026-11-02 never 0.6 https://aktiv8.io/news/n1m4hm9l/tiziana-announces-positive-topline-results-from-phase-2a-inform-ms-trial-of-intranasal-for 2026-11-02 never 0.6 https://aktiv8.io/news/n5e1kos/enlivex-announces-favorable-12-month-topline-data-from-phase-i-iia-allocetra-trial-demonst 2026-11-02 never 0.6 https://aktiv8.io/news/n13s2rgp/sofema-aviation-projects-250-000-delegate-milestone-amid-demand-for-multi-regulatory-compl 2026-11-02 never 0.6 https://aktiv8.io/news/ng9awr9/uniqure-announces-fda-acceptance-and-priority-review-of-the-biologics-license-application- 2026-11-02 never 0.6 https://aktiv8.io/news/nu1nwbt/agenus-announces-nature-medicine-publication-of-multicenter-unicorn-phase-2-trial-demonstr 2026-11-02 never 0.6 https://aktiv8.io/news/n1no52qr/alliance-releases-vietnam-biotech-supply-chain-report-following-dhs-update 2026-11-02 never 0.6 https://aktiv8.io/news/n1ihb0k3/contrario-medical-receives-fda-510-k-clearance-for-cyperus-sperm-separation-device 2026-11-02 never 0.6 https://aktiv8.io/news/n2zwcou/beeline-medicines-initiates-first-trial-in-lupus-pivotal-development-program-with-global-p 2026-11-02 never 0.6 https://aktiv8.io/news/n4yw02t/shanghai-junshi-biosciences-sehk-1877-reaches-three-phase-3-cancer-trial-milestones 2026-11-01 never 0.6 https://aktiv8.io/news/ndp77ae/stockwatch-gene-editing-shares-jump-on-esgct-data-fda-draft-guidance 2026-11-01 never 0.6 https://aktiv8.io/news/n18jgqng/perion-enters-into-definitive-merger-agreement-with-affle 2026-11-01 never 0.6 https://aktiv8.io/news/n1wmq0eb/takeda-pharmaceutical-s-orexin-gains-fda-approval-labroots 2026-11-01 never 0.6 https://aktiv8.io/news/n1t7y0sz/stocktwits-biotech-dealmaker-biomarin-s-fabry-disease-drug-candidate-license-dominates-slo 2026-10-31 never 0.6 https://aktiv8.io/news/ngv0rwh/zhimeng-biopharma-completes-enrollment-of-cb03-154-phase-2-3-als-trial-the-clinical-trial- 2026-10-31 never 0.6 https://aktiv8.io/news/n6p3y9x/ksat-and-morehead-state-university-partner-to-expand-lunar-communications-infrastructure 2026-10-31 never 0.6 https://aktiv8.io/news/n1rtrzuy/zhimeng-biopharma-has-completed-the-patients-enrollment-of-its-investigational-drug-cb03-1 2026-10-31 never 0.6 https://aktiv8.io/news/n1fki2t3/zhimeng-biopharma-has-completed-the-patients-enrollment-of-its-investigational-drug-cb03-1 2026-10-31 never 0.6 https://aktiv8.io/news/n10huuho/zhimeng-biopharma-has-completed-the-patients-enrollment-of-its-investigational-drug-cb03-1 2026-10-31 never 0.6 https://aktiv8.io/news/nwl9csm/moleculin-biotech-completes-dosing-in-phase-2-3-miracle-trial-for-annarac-the-clinical-tri 2026-10-31 never 0.6 https://aktiv8.io/news/nx0428f/atyr-pharma-nasdaq-atyr-efzofitimod-phase-3-data-published-in-the-lancet-supports-continue 2026-10-30 never 0.6 https://aktiv8.io/news/njhuw9s/recce-pharmaceuticals-advances-phase-3-program-and-strengthens-commercial-pathway-in-septe 2026-10-30 never 0.6 https://aktiv8.io/news/n1mjdslf/atyr-pharma-stock-faces-mixed-phase-3-readout-in-sarcoidosis-ad-hoc-news-de 2026-10-30 never 0.6 https://aktiv8.io/news/nltkds4/immunic-highlights-progressive-ms-research-and-phase-3-outlook-at-mstoronto2026-proactive- 2026-10-30 never 0.6 https://aktiv8.io/news/n1kj1a89/sanofi-considering-moonshot-treatments-as-m-a-targets-to-survive-dupixent-patent-cliff 2026-10-30 never 0.6 https://aktiv8.io/news/nkevoxr/under-armour-selects-tacticalgear-com-wholesale-as-strategic-tactical-distribution-partner 2026-10-30 never 0.6 https://aktiv8.io/news/n1wa8bx8/fractyl-health-strengthens-revita-patent-portfolio-as-it-advances-toward-fda-submission-an 2026-10-30 never 0.6 https://aktiv8.io/news/ngjy8pj/darwin-biotech-presented-randomized-phase-1-als-study-data-of-cell-free-alt001-and-u-s-pha 2026-10-30 never 0.6 https://aktiv8.io/news/n13vc78c/velo-nicotine-pouches-receive-u-s-fda-marketing-authorization 2026-10-30 never 0.6 https://aktiv8.io/news/nvifi1l/nrx-pharmaceuticals-nasdaq-nrxp-receives-fda-approval-of-preservative-free-ketamine-ahead- 2026-10-30 never 0.6 https://aktiv8.io/news/n14dz5b6/how-investors-may-respond-to-pfizer-pfe-phase-3-cancer-trial-win 2026-10-30 never 0.6 https://aktiv8.io/news/n6u0joy/gc-hanmi-license-fabry-disease-drug-to-biomarin-in-deal-worth-up-to-475-million-korea-biom 2026-10-30 never 0.6 https://aktiv8.io/news/n1yirx6r/after-clinical-trial-results-miami-biotech-firm-explores-sale-or-merger-the-business-journ 2026-10-30 never 0.6 https://aktiv8.io/news/n1lz1id3/molecular-partners-to-lay-off-up-to-44-of-workforce-in-radiotherapy-pivot 2026-10-30 never 0.6 https://aktiv8.io/news/n1lkc6f5/lilly-s-triple-action-drug-beats-novo-s-ozempic-in-phase-3-trial-emj 2026-10-30 never 0.6 https://aktiv8.io/news/ngctjhb/beyond-conventional-anti-tigit-hanchorbio-secures-taiwan-tfda-approval-for-hcb303-followin 2026-10-30 never 0.6 https://aktiv8.io/news/n123yvwg/us-fda-approves-inovio-s-treatment-for-rare-throat-disease-shares-surge 2026-10-30 never 0.6 https://aktiv8.io/news/nub6yde/atyr-pharma-nasdaq-atyr-efzofitimod-phase-3-data-published-in-the-lancet-supports-continue 2026-10-30 never 0.6 https://aktiv8.io/news/n1gie6nu/alkermes-expands-alks-7290-development-program-with-initiation-of-phase-2-study-for-the-ad 2026-10-30 never 0.6 https://aktiv8.io/news/nxmowq2/stat-fda-cms-scramble-to-avoid-regulatory-logjam-as-more-states-look-to-test-ai-in-clinica 2026-10-30 never 0.6 https://aktiv8.io/news/n1rvt21g/acumen-pharmaceuticals-announces-topline-results-from-phase-2-altitude-ad-clinical-trial-o 2026-10-30 never 0.6 https://aktiv8.io/news/ncjew01/ksat-and-morehead-state-university-partner-to-expand-lunar-communications-infrastructure 2026-10-30 never 0.6 https://aktiv8.io/news/nupf6le/gc-biopharma-hanmi-pharm-strike-475m-fabry-disease-drug-deal-with-biomarin-the-korea-heral 2026-10-30 never 0.6 https://aktiv8.io/news/n1orqqg3/inovio-announces-fda-accelerated-approval-of-voceryq-an-immunotherapy-to-reduce-the-freque 2026-10-30 never 0.6 https://aktiv8.io/news/n1se7360/beyond-conventional-anti-tigit-hanchorbio-secures-taiwan-tfda-approval-for-hcb303-followin 2026-10-30 never 0.6 https://aktiv8.io/news/n1nf9vck/hanlim-pharm-teams-up-with-japan-s-dci-partners-to-explore-biotech-investments-korea-biome 2026-10-30 never 0.6 https://aktiv8.io/news/n1xp3hvh/pretzel-therapeutics-receives-uk-regulatory-authorization-to-advance-px578-into-clinical-d 2026-10-30 never 0.6 https://aktiv8.io/news/n9btgmf/pfizer-reports-strong-phase-2-data-for-25-valent-pediatric-pcv-drug-topics 2026-10-30 never 0.6 https://aktiv8.io/news/n22j838/cytrellis-named-strategic-industry-partner-of-aesthetic-medicine-certificate-program-at-un 2026-10-30 never 0.6 https://aktiv8.io/news/n1kheum1/entangled-2026-summit-unites-leaders-in-quantum-computing-ai-and-biotech-to-explore-what-m 2026-10-29 never 0.6 https://aktiv8.io/news/n2p413t/azitra-inc-expands-eligibility-for-atr-04-phase-1-2-clinical-trial-to-include-patients-wit 2026-10-29 never 0.6 https://aktiv8.io/news/n8pmsve/pro-athlete-backed-skoka-raises-21-5-million-invests-15-million-in-fda-regulatory-program- 2026-10-29 never 0.6 https://aktiv8.io/news/n1gevjyb/biomarin-enters-into-exclusive-worldwide-license-agreement-with-gc-biopharma-and-hanmi-pha 2026-10-29 never 0.6 https://aktiv8.io/news/n41o3d8/geocomm-and-schooldog-partner-to-strengthen-school-safety-preparedness 2026-10-29 never 0.6 https://aktiv8.io/news/n1ef4zd7/kiora-pharmaceuticals-in-licenses-late-stage-oral-neuroprotective-calpain-inhibitor-for-ce 2026-10-29 never 0.6 https://aktiv8.io/news/nl52pfh/tangram-announces-first-participant-dosed-in-phase-1-trial-of-tgm-148-a-novel-investigatio 2026-10-29 never 0.6 https://aktiv8.io/news/n1m98rle/kymera-therapeutics-announces-third-quarter-2026-financial-results-and-reports-positive-re 2026-10-29 never 0.6 https://aktiv8.io/news/nowbay8/assembly-biosciences-doses-first-two-participants-in-phase-2-study-of-oral-ntcp-inhibitor- 2026-10-29 never 0.6 https://aktiv8.io/news/nbc835s/hutchmed-announces-sovleplenib-granted-us-fda-orphan-drug-designation-for-primary-immune-t 2026-10-29 never 0.6 https://aktiv8.io/news/nm7ffrh/radiant-achieves-industry-milestone-as-the-only-microreactor-design-to-secure-doe-safety-a 2026-10-29 never 0.6 https://aktiv8.io/news/nkzcqko/united-therapeutics-secures-fda-clearance-for-pah-phase-i-trial 2026-10-29 never 0.6 https://aktiv8.io/news/nrdwsfh/united-premier-soccer-league-names-corgi-insurance-its-official-insurance-partner 2026-10-29 never 0.6 https://aktiv8.io/news/nhu4yq/abbott-initiates-pivotal-trial-for-cephea-device-an-innovative-treatment-for-mitral-heart- 2026-10-29 never 0.6 https://aktiv8.io/news/n13ruckf/biotech-stocks-facing-fda-decision-in-november-2026-rttnews 2026-10-29 never 0.6 https://aktiv8.io/news/n1fqi8sy/azitra-inc-expands-eligibility-for-atr-04-phase-1-2-clinical-trial-to-include-patients-wit 2026-10-29 never 0.6 https://aktiv8.io/news/nwwhhnd/eloxx-pharmaceuticals-announces-fda-clearance-of-investigational-new-drug-application-for- 2026-10-29 never 0.6 https://aktiv8.io/news/nfjku8/norfolk-southern-and-schneider-partner-to-expand-domestic-intermodal-capacity-across-the-e 2026-10-29 never 0.6 https://aktiv8.io/news/n123x2g8/kymera-therapeutics-announces-third-quarter-2026-financial-results-and-reports-positive-re 2026-10-29 never 0.6 https://aktiv8.io/news/naimo7c/junshi-biosciences-announces-the-completion-of-first-patient-dosing-in-the-phase-3-clinica 2026-10-29 never 0.6 https://aktiv8.io/news/nmltjwo/eco-wave-power-announces-major-milestone-in-collaboration-with-fortune-500-energy-giant-bh 2026-10-29 never 0.6 https://aktiv8.io/news/n2dekx1/atyr-pharma-announces-publication-of-results-from-the-phase-3-efzo-fit-study-of-efzofitimo 2026-10-29 never 0.6 https://aktiv8.io/news/nj2go9r/neurosense-to-present-integrated-clinical-and-biomarker-evidence-shaping-primec-s-phase-3- 2026-10-29 never 0.6 https://aktiv8.io/news/n5341ac/neurosense-to-present-integrated-clinical-and-biomarker-evidence-shaping-primec-s-phase-3- 2026-10-29 never 0.6 https://aktiv8.io/news/non4q9z/immunocore-will-present-phase-1-data-for-brenetafusp-plus-kimmtrak-tebentafusp-tebn-in-met 2026-10-29 never 0.6 https://aktiv8.io/news/n1jdr6p/late-breaking-phase-3-reduce-2-data-show-clinically-meaningful-and-durable-serum-urate-low 2026-10-29 never 0.6 https://aktiv8.io/news/n1ky9uus/better-than-ozempic-retatrutide-delivers-double-ozempic-s-weight-loss-in-phase-3-trial-ndt 2026-10-29 never 0.6 https://aktiv8.io/news/n1gty6az/gi-windows-surgical-announces-fda-clearance-for-gastric-anastomosis 2026-10-29 never 0.6 https://aktiv8.io/news/n4uzf0j/viedoc-and-bioforum-partner-as-biogrid-joins-the-viedoc-verified-technology-partner-progra 2026-10-29 never 0.6 https://aktiv8.io/news/nqf1g3j/novavax-earns-125-million-milestone-as-sanofi-launches-phase-3-influenza-covid-19-combinat 2026-10-29 never 0.6 https://aktiv8.io/news/nawgdhm/eloxx-pharmaceuticals-announces-fda-clearance-of-investigational-new-drug-application-for- 2026-10-29 never 0.6 https://aktiv8.io/news/ndroq15/sonilo-and-musical-ai-partner-to-ensure-ai-music-empowers-creators-and-rewards-rights-hold 2026-10-29 never 0.6 https://aktiv8.io/news/n1837o8g/annovis-to-participate-in-u-s-biotech-day-2026-and-pharma-partnering-summit-2026 2026-10-29 never 0.6 https://aktiv8.io/news/n102asp1/junshi-biosciences-announces-the-completion-of-first-patient-dosing-in-the-phase-3-clinica 2026-10-29 never 0.6 https://aktiv8.io/news/n1c04uj1/roundup-biomarin-licenses-long-acting-fabry-enzyme-therapy-for-70-million-upfront-ferring- 2026-10-29 never 0.6 https://aktiv8.io/news/nbfku0w/geron-halts-phase-3-imetelstat-trial-in-relapsed-refractory-myelofibrosis-targeted-oncolog 2026-10-29 never 0.6 https://aktiv8.io/news/n6sg6fc/pharvaris-to-present-phase-3-data-on-oral-drug-for-hereditary-angioedema-at-acaai-2026-mee 2026-10-29 never 0.6 https://aktiv8.io/news/n6g5y8i/gc-biopharma-hanmi-pharmaceutical-license-fabry-disease-drug-to-biomarin-for-approximately 2026-10-29 never 0.6 https://aktiv8.io/news/ndv1ww4/biogen-to-present-new-data-across-alzheimer-s-disease-portfolio-at-ctad-2026 2026-10-29 never 0.6 https://aktiv8.io/news/n5s7l9x/neurosense-to-present-integrated-clinical-and-biomarker-evidence-shaping-primec-s-phase-3- 2026-10-29 never 0.6 https://aktiv8.io/news/n1rd8v3o/acrivon-announces-late-breaking-oral-plenary-presentation-of-early-phase-1-2-clinical-resu 2026-10-29 never 0.6 https://aktiv8.io/news/nw7pll0/neurosense-to-present-integrated-clinical-and-biomarker-evidence-shaping-primec-s-phase-3- 2026-10-29 never 0.6 https://aktiv8.io/news/n1br0doi/nrx-pharmaceuticals-nasdaq-nrxp-to-host-conference-call-on-october-30-2026-to-discuss-regu 2026-10-29 never 0.6 https://aktiv8.io/news/npmn5cn/ono-pharma-announces-results-from-five-phase-2-clinical-studies-of-ono-1110-an-endocannabi 2026-10-29 never 0.6 https://aktiv8.io/news/nxvbtov/xenon-announces-positive-phase-1-and-new-preclinical-data-at-iasp-2026-supporting-advancem 2026-10-29 never 0.6 https://aktiv8.io/news/n1xts0zh/eli-lilly-scraps-phase-2-alzheimer-s-program-after-drug-falls-short-of-expectations 2026-10-29 never 0.6 https://aktiv8.io/news/n1s4dwxw/biomarin-enters-into-exclusive-worldwide-license-agreement-with-gc-biopharma-and-hanmi-pha 2026-10-29 never 0.6 https://aktiv8.io/news/n1o0tr1a/biotech-stocks-facing-fda-decision-in-november-2026-rttnews 2026-10-29 never 0.6 https://aktiv8.io/news/n1xsz2le/stat-hhs-green-lights-six-peptides-despite-concerns-from-fda-scientists 2026-10-29 never 0.6 https://aktiv8.io/news/n1qqyhcc/instylla-s-embrace-hydrogel-embolic-system-receives-fda-approval-for-peripheral-arterial-b 2026-10-29 never 0.6 https://aktiv8.io/news/n1ldzasv/stat-el-sayed-claps-back-at-rfk-jr-and-fda-s-enforcement-discretion-on-peptides 2026-10-29 never 0.6 https://aktiv8.io/news/n1lpil9k/geron-ends-phase-3-imetelstat-myelofibrosis-trial-after-independent-monitors-say-survival- 2026-10-29 never 0.6 https://aktiv8.io/news/n1t3bxup/cerenome-completes-enrollment-in-phase-2-respect-gbm-trial-of-reyobiq-in-recurrent-gliobla 2026-10-29 never 0.6 https://aktiv8.io/news/n9yvk1p/jazz-s-820m-actio-buyout-gives-rise-to-setara-armed-with-90m-series-a 2026-10-29 never 0.6 https://aktiv8.io/news/ngdmjv7/protina-secures-osteoarthritis-drug-patents-in-8-countries-due-diligence-underway-with-2-j 2026-10-29 never 0.6 https://aktiv8.io/news/n1i6rkpo/geron-s-rytelo-stumbles-in-phase-3-as-novartis-gears-up-for-post-jak-inhibitor-blood-cance 2026-10-29 never 0.6 https://aktiv8.io/news/nimoc9s/elicio-therapeutics-to-present-phase-2-amplify-7p-results-at-the-sitc-2026-annual-meeting- 2026-10-29 never 0.6 https://aktiv8.io/news/nld5yvy/biomarin-inks-license-agreement-for-fabry-disease-therapy-the-pharma-letter 2026-10-29 never 0.6 https://aktiv8.io/news/n10pfpln/eloxx-pharmaceuticals-announces-fda-clearance-of-investigational-new-drug-application-for- 2026-10-29 never 0.6 https://aktiv8.io/news/nd67vek/nuvation-bio-to-expand-pivotal-phase-3-sigma-study-of-safusidenib-for-idh1-mutant-glioma-t 2026-10-29 never 0.6 https://aktiv8.io/news/n16xhxid/entangled-2026-summit-unites-leaders-in-quantum-computing-ai-and-biotech-to-explore-what-m 2026-10-29 never 0.6 https://aktiv8.io/news/nt1a1s/nuvation-bio-to-expand-pivotal-phase-3-sigma-study-of-safusidenib-for-idh1-mutant-glioma-t 2026-10-29 never 0.6 https://aktiv8.io/news/ngtc7v8/ose-immunotherapeutics-reports-additional-positive-results-of-combi-ted-phase-2-randomized 2026-10-29 never 0.6 https://aktiv8.io/news/nx7sbg7/azitra-inc-expands-eligibility-for-atr-04-phase-1-2-clinical-trial-to-include-patients-wit 2026-10-29 never 0.6 https://aktiv8.io/news/nfyn448/novavax-earns-125-million-milestone-as-sanofi-launches-phase-3-influenza-covid-19-combinat 2026-10-29 never 0.6 https://aktiv8.io/news/n1rc6q10/cerevasc-receives-fda-ide-approval-to-evaluate-the-eshunt-system-in-patients-with-alzheime 2026-10-29 never 0.6 https://aktiv8.io/news/nlraic6/frontier-medicines-announces-fda-allowance-to-proceed-under-an-ind-for-fmc-242-a-novel-cov 2026-10-29 never 0.6 https://aktiv8.io/news/n1rq8x7z/immunocore-will-present-phase-1-data-for-brenetafusp-plus-kimmtrak-tebentafusp-tebn-in-met 2026-10-29 never 0.6 https://aktiv8.io/news/n1i6sii9/lilly-s-retatrutide-scores-another-phase-3-win-outperforming-ozempic-in-head-to-head-study 2026-10-29 never 0.6 https://aktiv8.io/news/nsu5sx8/chegg-skills-and-powertrain-partner-to-deliver-ai-and-workforce-training-programs-across-g 2026-10-29 never 0.6 https://aktiv8.io/news/n1344n2d/opinion-stat-is-ai-more-a-partner-competitor-or-crutch-for-biomedical-scientists 2026-10-29 never 0.6 https://aktiv8.io/news/n6oz2do/late-breaking-phase-3-reduce-2-data-show-clinically-meaningful-and-durable-serum-urate-low 2026-10-29 never 0.6 https://aktiv8.io/news/n4zxvhp/ascletis-challenger-to-lilly-s-foundayo-hits-goals-in-phase-2-diabetes-trial 2026-10-29 never 0.6 https://aktiv8.io/news/n17ldfrb/rafael-holdings-announces-submission-of-new-drug-application-to-fda-for-trappsol-cyclo-rem 2026-10-29 never 0.6 https://aktiv8.io/news/nyfkg4o/palvella-announces-fda-acceptance-and-priority-review-of 2026-10-28 never 0.6 https://aktiv8.io/news/nva9xi6/subaru-of-america-recognized-by-u-s-chamber-of-commerce-foundation-for-partnership-with-bl 2026-10-28 never 0.6 https://aktiv8.io/news/n13b17yi/brainomix-ai-imaging-analysis-of-phase-3-charm-trial-identifies-promising-treatment-signal 2026-10-28 never 0.6 https://aktiv8.io/news/n29bfby/ripple-and-coinbase-partner-to-expand-access-to-ripple-usd 2026-10-28 never 0.6 https://aktiv8.io/news/n1fudodc/metavia-to-present-phase-1-clinical-trial-data-for-da-1726-in-oral-presentation-at-the-pre 2026-10-28 never 0.6 https://aktiv8.io/news/nwuwk61/palvella-announces-fda-acceptance-and-priority-review-of-qtorin-rapamycin-nda-february-28- 2026-10-28 never 0.6 https://aktiv8.io/news/nus73dj/inventiva-iva-vs-crsp-and-mdgl-can-lanifibranor-s-phase-3-trial-unlock-62-upside 2026-10-28 never 0.6 https://aktiv8.io/news/n61rt46/luckener-at-lutian-global-energy-partner-conference-2026-a-new-milestone-in-global-growth 2026-10-28 never 0.6 https://aktiv8.io/news/n1rnwe7l/monte-rosa-therapeutics-announces-milestone-achievement-associated-with-second-phase-2-cli 2026-10-28 never 0.6 https://aktiv8.io/news/n1960we2/genmab-s-8b-merus-bet-delivers-as-bispecific-combo-halves-risk-of-death-in-phase-3 2026-10-28 never 0.6 https://aktiv8.io/news/n4exwyc/metavia-to-present-phase-1-clinical-trial-data-for-da-1726-in-oral-presentation-at-the-pre 2026-10-28 never 0.6 https://aktiv8.io/news/nugqibi/genmab-s-8b-merus-bet-delivers-as-bispecific-combo-halves-risk-of-death-in-phase-3 2026-10-28 never 0.6 https://aktiv8.io/news/nrpaw3f/lilly-s-retatrutide-bests-ozempic-on-blood-sugar-weight-loss-in-phase-3-diabetes-showdown 2026-10-28 never 0.6 https://aktiv8.io/news/n1afhcqv/astellas-audax-ink-global-license-agreement-for-immuno-oncology-candidate-contract-pharma 2026-10-28 never 0.6 https://aktiv8.io/news/n1r4xhv7/empatica-launches-wellpd-an-fda-cleared-parkinson-s-monitoring-device-for-home-use 2026-10-28 never 0.6 https://aktiv8.io/news/nstp3gh/focused-cryo-completes-first-clinical-cases-with-its-fda-cleared-directional-cryoablation- 2026-10-28 never 0.6 https://aktiv8.io/news/n1m83s6n/imda-and-nuh-partner-in-first-open-innovation-platform-collaboration-in-public-healthcare 2026-10-28 never 0.6 https://aktiv8.io/news/n19uj5za/abbvie-seeks-fda-approval-for-multiple-myeloma-drug-candidate-medwatch 2026-10-28 never 0.6 https://aktiv8.io/news/n1arompg/metavia-to-present-phase-1-clinical-trial-data-for-da-1726-in-oral-presentation-at-the-pre 2026-10-28 never 0.6 https://aktiv8.io/news/naglwre/geron-corporation-provides-update-on-phase-3-impactmf-clinical-trial-of-imetelstat-in-rela 2026-10-28 never 0.6 https://aktiv8.io/news/n70y993/appian-and-psi-cro-form-strategic-partnership-to-advance-ai-driven-clinical-trial-operatio 2026-10-28 never 0.6 https://aktiv8.io/news/nku4wt7/kymera-therapeutics-to-announce-kt-579-phase-1-healthy-volunteer-trial-results-on-october- 2026-10-28 never 0.6 https://aktiv8.io/news/nl228x9/deep-breathe-receives-fda-clearance-for-the-first-ai-dedicated-to-detecting-absent-lung-sl 2026-10-28 never 0.6 https://aktiv8.io/news/n1vhyta6/big-pharma-ai-firms-sign-3-8b-this-month-70-alliances-in-2025 2026-10-28 never 0.6 https://aktiv8.io/news/ng71lkt/stat-hhs-moves-to-allow-compounding-of-some-unapproved-peptides 2026-10-28 never 0.6 https://aktiv8.io/news/n15yc3lf/geron-stock-tumbles-after-halting-phase-3-trial 2026-10-28 never 0.6 https://aktiv8.io/news/n1oilce/datalogix-ai-and-zenda-financial-partner-to-help-business-owners-explore-ai-data-licensing 2026-10-28 never 0.6 https://aktiv8.io/news/n1b5ym6k/eli-lilly-s-retatrutide-outperforms-ozempic-in-phase-3-trial-bo-gurufocus 2026-10-28 never 0.6 https://aktiv8.io/news/nxq8f10/astellas-and-audax-biosciences-enter-exclusive-option-and-license-agreement-for-dax-044-a- 2026-10-28 never 0.6 https://aktiv8.io/news/nsfiae5/personalized-mrna-vaccine-reduces-melanoma-recurrence-risk-in-phase-3-trial-oncology-news- 2026-10-28 never 0.6 https://aktiv8.io/news/n1ind9to/united-therapeutics-announces-fda-clearance-to-proceed-with-clinical-trial-for-treprostini 2026-10-28 never 0.6 https://aktiv8.io/news/n1ljb6r4/psc-partners-issues-a-call-to-action-in-response-to-the-fda-rare-disease-framework-public- 2026-10-28 never 0.6 https://aktiv8.io/news/nvp9hne/monte-rosa-therapeutics-announces-milestone-achievement-associated-with-second-phase-2-cli 2026-10-28 never 0.6 https://aktiv8.io/news/n1dkvnlq/novocure-to-evaluate-tumor-treating-fields-therapy-with-vs-7375-an-oral-kras-g12d-on-off-i 2026-10-28 never 0.6 https://aktiv8.io/news/nc02do8/otsuka-presents-final-phase-3-visionary-results-at-asn-demonstrating-sibeprenlimab-stabili 2026-10-28 never 0.6 https://aktiv8.io/news/neeix1i/genmab-stock-gmab-soars-over-30-on-strong-phase-3-results-for-the-company-s-head-and-neck- 2026-10-28 never 0.6 https://aktiv8.io/news/nkft92c/lilly-s-retatrutide-bests-ozempic-on-blood-sugar-weight-loss-in-phase-3-diabetes-showdown 2026-10-28 never 0.6 https://aktiv8.io/news/nn5rul2/kymera-therapeutics-to-announce-kt-579-phase-1-healthy-volunteer-trial-results-on-october- 2026-10-28 never 0.6 https://aktiv8.io/news/nvqv9qk/brainomix-ai-imaging-analysis-of-phase-3-charm-trial-identifies-promising-treatment-signal 2026-10-28 never 0.6 https://aktiv8.io/news/nq3zd2n/junshi-biosciences-announces-final-analysis-results-of-the-phase-3-neotorch-study-at-esmo- 2026-10-28 never 0.6 https://aktiv8.io/news/nynwn1j/actinogen-pivotal-alzheimer-s-disease-trial-database-lock-milestone-topline-results-on-tra 2026-10-28 never 0.6 https://aktiv8.io/news/n1s88dlc/iovance-biotherapeutics-to-host-webcast-on-positive-data-for-til-therapy-in-metastatic-non 2026-10-28 never 0.6 https://aktiv8.io/news/n1huvm78/appian-and-psi-cro-form-strategic-partnership-to-advance-ai-driven-clinical-trial-operatio 2026-10-28 never 0.6 https://aktiv8.io/news/n1g5mgzy/adagene-announces-dosing-of-first-patient-in-phase-1-study-of-muzastotug-in-combination-wi 2026-10-28 never 0.6 https://aktiv8.io/news/n1tnurb0/blue-lake-biotechnology-secures-5-million-grant-to-support-ongoing-pediatric-phase-1-2a-cl 2026-10-28 never 0.6 https://aktiv8.io/news/n1aeag0f/novocure-to-evaluate-tumor-treating-fields-therapy-with-vs-7375-an-oral-kras-g12d-on-off-i 2026-10-28 never 0.6 https://aktiv8.io/news/n1nxbz6b/sellas-life-sciences-reaches-key-milestone-in-phase-3-regal-trial-for-aml-treatment-ssbcra 2026-10-28 never 0.6 https://aktiv8.io/news/n1rvrah/nxera-pharma-secures-exclusive-rights-to-fabry-disease-phase-3-oral-therapy-candidate-luce 2026-10-28 never 0.6 https://aktiv8.io/news/n1yv3o04/positive-melanoma-mrna-vaccine-trial-data-sparks-personalized-medicine-hope-the-scientist 2026-10-28 never 0.6 https://aktiv8.io/news/nqwj4j2/adjuvia-therapeutics-initiates-phase-1-clinical-trial-of-ati-105-for-friedreich-s-ataxia 2026-10-28 never 0.6 https://aktiv8.io/news/n3vbbfg/palvella-announces-fda-acceptance-and-priority-review-of-qtorin-rapamycin-nda-february-28- 2026-10-28 never 0.6 https://aktiv8.io/news/n1kmh4rs/mineralys-therapeutics-announces-publication-of-phase-2-explore-ckd-trial-results-for-loru 2026-10-28 never 0.6 https://aktiv8.io/news/nfs6a91/electrocore-inc-submits-510-k-premarket-notification-to-fda-seeking-clearance-of-quell-for 2026-10-28 never 0.6 https://aktiv8.io/news/n1h1ttqw/alzheimer-s-drug-discovery-foundation-s-diagnostics-accelerator-licenses-speechdx-dataset- 2026-10-28 never 0.6 https://aktiv8.io/news/npzdsn4/united-therapeutics-announces-fda-clearance-to-proceed-with-clinical-trial-for-treprostini 2026-10-28 never 0.6 https://aktiv8.io/news/n10790kk/palvella-wins-fda-priority-review-for-qtorin-rapamycin-pdufa-date-feb-28-2027-minichart 2026-10-28 never 0.6 https://aktiv8.io/news/n1fo4ru1/adagene-announces-dosing-of-first-patient-in-phase-1-study-of-muzastotug-in-combination-wi 2026-10-28 never 0.6 https://aktiv8.io/news/ns3trq4/alume-biosciences-announces-fda-acceptance-of-new-drug-application-for-bevonescein-for-use 2026-10-28 never 0.6 https://aktiv8.io/news/n8ed1x4/novartis-presents-positive-results-from-two-phase-3-trials-for-relapsing-ms-pmlive 2026-10-28 never 0.6 https://aktiv8.io/news/nrvoqsp/luckener-at-lutian-global-energy-partner-conference-2026-a-new-milestone-in-global-growth 2026-10-28 never 0.6 https://aktiv8.io/news/n1ybns73/hervolution-publishes-foundational-data-demonstrating-rationally-engineered-herv-k-antigen 2026-10-28 never 0.6 https://aktiv8.io/news/nvfc52p/geron-corporation-provides-update-on-phase-3-impactmf-clinical-trial-of-imetelstat-in-rela 2026-10-28 never 0.6 https://aktiv8.io/news/n7urt3q/fda-grants-breakthrough-device-designation-to-pharaoh-neuro-s-neurapheresis-csf-management 2026-10-28 never 0.6 https://aktiv8.io/news/n1jblia4/geron-corporation-provides-update-on-phase-3-impactmf 2026-10-28 never 0.6 https://aktiv8.io/news/ntu88pc/junshi-biosciences-announces-final-analysis-results-of-the-phase-3-neotorch-study-at-esmo- 2026-10-28 never 0.6 https://aktiv8.io/news/ny1ijs3/docquity-extends-asian-healthcare-intelligence-to-the-middle-east-through-strategic-partne 2026-10-28 never 0.6 https://aktiv8.io/news/n1dd2w7q/geron-scraps-phase-3-myelofibrosis-trial-shares-fall-12-biggo-finance 2026-10-28 never 0.6 https://aktiv8.io/news/nct4lde/junshi-biosciences-announces-final-analysis-results-of-the-phase-3-neotorch-study-at-esmo- 2026-10-28 never 0.6 https://aktiv8.io/news/n1y5i44c/mineralys-therapeutics-announces-publication-of-phase-2-explore-ckd-trial-results-for-loru 2026-10-28 never 0.6 https://aktiv8.io/news/nutc1o8/cumberland-pharmaceuticals-inc-cpix-discusses-duchenne-cardiomyopathy-nda-submission-and-p 2026-10-28 never 0.6 https://aktiv8.io/news/nfvxoe0/appian-and-psi-cro-form-strategic-partnership-to-advance-ai-driven-clinical-trial-operatio 2026-10-28 never 0.6 https://aktiv8.io/news/n5knf65/melbourne-cancer-therapy-start-up-wins-2b-deal-with-japan-s-astellas-afr 2026-10-27 never 0.6 https://aktiv8.io/news/n1lgyxuq/abionyx-pharma-finalizes-the-structuring-of-its-cer-001-bioproduction-chain-through-a-stra 2026-10-27 never 0.6 https://aktiv8.io/news/nmdakz3/ripple-and-robinhood-partner-to-power-the-next-generation-of-finance 2026-10-27 never 0.6 https://aktiv8.io/news/nicsqwb/chidamide-plus-nivolumab-shows-potential-as-new-standard-of-care-in-advanced-melanoma-redu 2026-10-27 never 0.6 https://aktiv8.io/news/n127hhjt/treasury-s-coins-rule-bars-us-equity-in-chinese-biotech-steve-uden-says-licensing-survives 2026-10-27 never 0.6 https://aktiv8.io/news/n1tihnn8/mdt-bridge-phase-2-data-signals-a-protocol-driven-model-for-adaptive-resectability-assessm 2026-10-27 never 0.6 https://aktiv8.io/news/na9otl7/stevanato-group-and-aptar-pharma-collaborate-to-help-accelerate-pre-filled-syringe-system- 2026-10-27 never 0.6 https://aktiv8.io/news/nv586ii/monebo-and-innolitics-secure-fda-510-k-clearance-for-a-cross-platform-ecg-arrhythmia-analy 2026-10-27 never 0.6 https://aktiv8.io/news/nhvvsr1/enhertu-approved-in-the-eu-as-adjuvant-treatment-for-patients-with-residual-disease-after- 2026-10-27 never 0.6 https://aktiv8.io/news/n11vu0b0/ampera-and-imperial-college-london-partner-to-develop-physics-grounded-ai-platform-for-adv 2026-10-27 never 0.6 https://aktiv8.io/news/nlhbl8k/powerful-medical-granted-cpt-code-for-ai-ecg-heart-attack-detection-weeks-after-fda-de-nov 2026-10-27 never 0.6 https://aktiv8.io/news/nyhyyn2/ciklum-and-nice-partner-to-bring-agentic-ai-to-enterprise-customer-experiences 2026-10-27 never 0.6 https://aktiv8.io/news/nicy2cm/enveda-collaborates-with-anthropic-to-accelerate-drug-development 2026-10-27 never 0.6 https://aktiv8.io/news/n1mml172/innate-pharma-pacific-9-phase-3-trial-readout-timing-updated-to-h1-2027 2026-10-27 never 0.6 https://aktiv8.io/news/nenbxww/revolune-and-concept-life-sciences-partner-to-help-customers-transition-multiplex-if-assay 2026-10-27 never 0.6 https://aktiv8.io/news/n18c7web/rumi-therapeutics-announces-licensing-agreement-with-enthorin-therapeutics-to-advance-rtx- 2026-10-27 never 0.6 https://aktiv8.io/news/n577n91/pfizer-s-elrexfio-outperforms-standard-regimens-and-meets-primary-endpoint-in-phase-3-stud 2026-10-27 never 0.6 https://aktiv8.io/news/n1782vqz/tonix-pharmaceuticals-presented-an-analysis-of-phase-3-data-demonstrating-tonmya-improved- 2026-10-27 never 0.6 https://aktiv8.io/news/nb7odn1/vincora-receives-fda-approval-to-initiate-u-s-early-feasibility-study-of-transcatheter-cho 2026-10-27 never 0.6 https://aktiv8.io/news/n1y6cusn/hengrui-pharma-reports-88-9-rise-in-2026-third-quarter-profit-on-licensing-deals 2026-10-27 never 0.6 https://aktiv8.io/news/no17pm2/workpro-tools-completes-sixth-year-of-partnership-with-national-breast-cancer-foundation-i 2026-10-27 never 0.6 https://aktiv8.io/news/n13mrp54/beam-therapeutics-reports-initial-clinical-data-from-phase-1-2-trial-of-beam-301-demonstra 2026-10-27 never 0.6 https://aktiv8.io/news/njcm24t/futureman-digital-named-statamic-s-first-and-only-enterprise-partner-in-north-america 2026-10-27 never 0.6 https://aktiv8.io/news/n335q6d/pfizer-says-phase-3-magnetismm-32-study-met-primary-endpoint-tipranks 2026-10-27 never 0.6 https://aktiv8.io/news/nqypexq/aptar-pharma-and-stevanato-group-collaborate-to-help-accelerate-pre-filled-syringe-system- 2026-10-27 never 0.6 https://aktiv8.io/news/n1535djx/cullinan-therapeutics-advances-velinotamig-into-global-clinical-development-for-autoimmune 2026-10-27 never 0.6 https://aktiv8.io/news/n14m36wy/opko-health-s-opko-biologics-doses-first-participant-in-phase-1-2a-trial-of-opk-8801001-fo 2026-10-27 never 0.6 https://aktiv8.io/news/npwqe8q/atelerix-and-frontier-space-partner-to-enable-biological-sample-preservation-for-space-mis 2026-10-27 never 0.6 https://aktiv8.io/news/n1ymp8xd/pfizer-s-elrexfio-outperforms-standard-regimens-and-meets-primary-endpoint-in-phase-3-stud 2026-10-27 never 0.6 https://aktiv8.io/news/n12u9ji0/deep-reasoning-ai-and-innolitics-achieve-fda-510-k-clearance-for-neurodr-ai-software-for-n 2026-10-27 never 0.6 https://aktiv8.io/news/nztyhmq/genomate-health-vivamed-biopharma-aim-to-repurpose-cancer-drugs-in-new-collaboration-genom 2026-10-27 never 0.6 https://aktiv8.io/news/nxwamty/camp4-therapeutics-receives-clinical-trial-application-approval-for-phase-1-2-clinical-tri 2026-10-27 never 0.6 https://aktiv8.io/news/n1apwxom/pharming-group-reports-third-quarter-2026-financial-results-strong-revenue-growth-joenja-a 2026-10-27 never 0.6 https://aktiv8.io/news/n1xfsd9l/acurastem-receives-hoffman-als-clinical-trial-award-to-support-phase-1-trial-of-as-241-the 2026-10-27 never 0.6 https://aktiv8.io/news/n3ecp01/beeline-medicines-to-present-results-from-the-phase-2-trial-of-afimetoran-in-systemic-lupu 2026-10-27 never 0.6 https://aktiv8.io/news/nn61wee/vanda-eyes-glp-1-nausea-indication-with-nereus-phase-3-win-in-hand-fierce-pharma 2026-10-27 never 0.6 https://aktiv8.io/news/nm0omum/fda-selects-patient-led-nonprofit-to-develop-pancreatitis-flare-endpoint-for-clinical-tria 2026-10-27 never 0.6 https://aktiv8.io/news/n928xel/syncromune-reports-long-term-data-from-phase-1-study-in-metastatic-prostate-cancer-with-in 2026-10-27 never 0.6 https://aktiv8.io/news/naoq6ud/cullinan-therapeutics-advances-velinotamig-into-global-clinical-development-for-autoimmune 2026-10-27 never 0.6 https://aktiv8.io/news/nb549do/cumberland-pharmaceuticals-the-fda-s-phase-3-question-is-hard-to-ignore-nasdaq-cpix 2026-10-27 never 0.6 https://aktiv8.io/news/nyzrm1s/pfizer-s-elrexfio-outperforms-standard-regimens-and-meets-primary-endpoint-in-phase-3-stud 2026-10-27 never 0.6 https://aktiv8.io/news/nllf1wi/orka-001-achieves-61-complete-skin-clearance-in-phase-2b-psoriasis-trial-the-clinical-tria 2026-10-27 never 0.6 https://aktiv8.io/news/n5b1du0/capitainer-initiates-clinical-sampling-for-hba1c-fda-510-k-study 2026-10-27 never 0.6 https://aktiv8.io/news/nuo9aky/aptar-pharma-acquires-pulmotree-expanding-growth-opportunities-in-next-generation-pulmonar 2026-10-27 never 0.6 https://aktiv8.io/news/n136gikt/merakris-advances-potentially-pivotal-mtx-001-phase-2-3-strategy-following-fda-pre-ind-mee 2026-10-27 never 0.6 https://aktiv8.io/news/n1sbbud3/pfizer-pfe-fda-approvals-pdufa-dates-drug-alerts-2026-pfe-marketbeat 2026-10-27 never 0.6 https://aktiv8.io/news/n1b9nslp/ferring-to-acquire-next-gen-ivf-startup-gameto-for-up-to-1-4b 2026-10-27 never 0.6 https://aktiv8.io/news/n1itkg49/innate-pharma-pacific-9-phase-3-trial-readout-timing-updated-to-h1-2027-ipha-stock-news 2026-10-27 never 0.6 https://aktiv8.io/news/nh5h1av/pyxis-oncology-to-present-micvotabart-pelidotin-micvo-phase-1-monotherapy-data-in-late-bre 2026-10-27 never 0.6 https://aktiv8.io/news/nytbf8x/slingshot-insurance-and-skyward-group-partner-to-accelerate-growth-in-embedded-insurance 2026-10-27 never 0.6 https://aktiv8.io/news/ny887pk/nord-and-amgen-launch-learning-collaborative-to-improve-rare-disease-diagnosis-and-care 2026-10-27 never 0.6 https://aktiv8.io/news/n1hu8vq0/blue-cross-blue-shield-of-massachusetts-collaborates-with-medzown-to-improve-clinical-tria 2026-10-27 never 0.6 https://aktiv8.io/news/n8h47gu/reg-rtw-biotech-opp-corxel-us-to-go-public-via-merger-with-amanat-tradingview 2026-10-27 never 0.6 https://aktiv8.io/news/n113e6zg/forlong-biotechnology-announces-first-patient-dosed-in-phase-1-clinical-trial-of-subcutane 2026-10-27 never 0.6 https://aktiv8.io/news/n11ajr3u/capitainer-initiates-clinical-sampling-for-hba1c-fda-510-k-study 2026-10-27 never 0.6 https://aktiv8.io/news/n1h6z8ox/purespring-therapeutics-advances-kidney-targeted-gene-therapy-ps-003-towards-the-clinic-in 2026-10-27 never 0.6 https://aktiv8.io/news/n10riirp/abbvie-submits-biologics-license-application-bla-for-etentamig-to-u-s-fda-for-adults-livin 2026-10-27 never 0.6 https://aktiv8.io/news/n1mp2wxu/abbvie-submits-biologics-license-application-bla-for-etentamig-to-u-s-fda-for-adults-livin 2026-10-27 never 0.6 https://aktiv8.io/news/n177cytj/vir-biotechnology-a-big-pharma-collaboration-and-2-clinical-catalysts-this-quarter-vir 2026-10-27 never 0.6 https://aktiv8.io/news/nizky6z/revolune-and-concept-life-sciences-partner-to-help-customers-transition-multiplex-if-assay 2026-10-27 never 0.6 https://aktiv8.io/news/ncwvqeo/stat-fda-offers-new-details-on-quicker-approval-pathway-for-personalized-gene-therapies 2026-10-27 never 0.6 https://aktiv8.io/news/nojp3lc/u-s-clamps-down-on-china-biotech-investment-dilemma-over-new-drug-collaboration 2026-10-27 never 0.6 https://aktiv8.io/news/npkzxh3/capitainer-initiates-clinical-sampling-for-hba1c-fda-510-k-study 2026-10-27 never 0.6 https://aktiv8.io/news/n1ouw526/carnyx-therapeutics-advances-lead-oral-sleep-candidate-cnyx-005-into-ind-enabling-developm 2026-10-27 never 0.6 https://aktiv8.io/news/n1s8k549/vincora-receives-fda-approval-to-initiate-u-s-early-feasibility-study-of-transcatheter-cho 2026-10-27 never 0.6 https://aktiv8.io/news/n1kb1al/astellas-and-audax-biosciences-enter-exclusive-option-and-license-agreement-for-dax-044-a- 2026-10-27 never 0.6 https://aktiv8.io/news/n11zd8gk/acurastem-receives-hoffman-als-clinical-trial-award-to-support-phase-1-trial-of-as-241-the 2026-10-27 never 0.6 https://aktiv8.io/news/nwgau2r/octant-receives-fda-orphan-drug-designation-for-oct-980-for-the-treatment-of-retinitis-pig 2026-10-27 never 0.6 https://aktiv8.io/news/nzxufu3/biontech-and-dualitybio-announce-topline-results-of-the-dynasty-breast02-global-phase-3-cl 2026-10-26 never 0.6 https://aktiv8.io/news/n1nlf1e8/sacituzumab-tirumotecan-improved-overall-survival-versus-platinum-chemotherapy-in-company- 2026-10-26 never 0.6 https://aktiv8.io/news/n2idmw8/spicy-organic-names-annatto-the-natural-answer-to-fda-s-synthetic-dye-phase-out 2026-10-26 never 0.6 https://aktiv8.io/news/n18y3xsg/esmo-in-sac-tmt-s-first-global-phase-3-win-merck-sees-pretty-consistent-data-with-china-fi 2026-10-26 never 0.6 https://aktiv8.io/news/new65r/biontech-and-dualitybio-announce-topline-results-of-the-dynasty-breast02-global-phase-3-cl 2026-10-26 never 0.6 https://aktiv8.io/news/nfzhum5/cumberland-announces-ifetroban-nda-filing-plan-after-shares-plummet 2026-10-26 never 0.6 https://aktiv8.io/news/n16zgy5c/xencor-presents-phase-1-dose-selection-data-for-xmab819-a-potential-first-in-class-enpp3-x 2026-10-26 never 0.6 https://aktiv8.io/news/n1gl1xg5/novartis-reports-lower-relapse-rates-and-no-hy-s-law-cases-in-phase-3-remibrutinib-ms-tria 2026-10-26 never 0.6 https://aktiv8.io/news/n1uri3tj/roche-announces-phase-3-results-for-kras-g12c-mutated-non-small-cell-lung-cancer-pmlive 2026-10-26 never 0.6 https://aktiv8.io/news/n1f57fsc/stocktwits-pharma-pulse-big-pharma-earnings-cancer-updates-and-2-fda-deadlines-the-week-s- 2026-10-26 never 0.6 https://aktiv8.io/news/n19jl95t/biontech-and-dualitybio-announce-topline-results-of-the-dynasty-breast02-global-phase-3-cl 2026-10-26 never 0.6 https://aktiv8.io/news/n6ux73w/sumitomo-pharma-america-announces-enzomenib-dsp-5336-receives-fda-breakthrough-therapy-des 2026-10-26 never 0.6 https://aktiv8.io/news/nbjtcj0/cisco-expands-partner-opportunity-with-new-cisco-360-program-updates-high-yield-customer-e 2026-10-26 never 0.6 https://aktiv8.io/news/n1mlggl9/the-enzyme-nobody-watched-how-mitapivat-s-phase-3-win-rewrites-the-rules-for-sickle-cell-d 2026-10-26 never 0.6 https://aktiv8.io/news/n1ikygvj/equillium-announces-first-subject-dosed-in-phase-1-clinical-trial-of-eq504 2026-10-26 never 0.6 https://aktiv8.io/news/ngy0vha/homegrown-singapore-brand-radar-tyres-extends-its-global-sporting-footprint-as-official-pa 2026-10-26 never 0.6 https://aktiv8.io/news/n1s4j3fv/aptar-pharma-acquires-pulmotree-expanding-growth-opportunities-in-next-generation-pulmonar 2026-10-26 never 0.6 https://aktiv8.io/news/n1xgttza/pfizer-s-talzenna-plus-xtandi-fda-approved-for-an-earlier-metastatic-prostate-cancer-treat 2026-10-26 never 0.6 https://aktiv8.io/news/na8tzbb/celcuity-celc-fda-approvals-pdufa-dates-drug-alerts-2026-celc-marketbeat 2026-10-26 never 0.6 https://aktiv8.io/news/n1omnvtf/biontech-sees-limited-benefit-to-adc-after-phase-3-reveals-modest-efficacy-ild-cases 2026-10-26 never 0.6 https://aktiv8.io/news/n1511u9m/cognizant-and-ebrd-partner-to-accelerate-digital-transformation-through-ai-led-outcome-dri 2026-10-26 never 0.6 https://aktiv8.io/news/n7sgwvi/u-s-fda-drops-tb-testing-requirement-for-skyrizi-following-npf-medical-board-guidance 2026-10-26 never 0.6 https://aktiv8.io/news/n17ja7ft/al-s-pharma-reports-new-ap-101-phase-2-weight-data-and-outlines-phase-3-clinical-trial-in- 2026-10-26 never 0.6 https://aktiv8.io/news/n1x00bdl/sanofi-sny-fda-approvals-pdufa-dates-drug-alerts-2026-sny-marketbeat 2026-10-26 never 0.6 https://aktiv8.io/news/nj51nq7/cashmere-and-american-physical-society-partner-to-bring-ai-discovery-of-physics-research-t 2026-10-26 never 0.6 https://aktiv8.io/news/nzpu0bo/macrogenics-announces-positive-interim-phase-2-linnet-results-for-lorigerlimab-in-advanced 2026-10-26 never 0.6 https://aktiv8.io/news/n1t0db0z/former-fda-head-steve-hahn-joins-breakbio-a-personalized-cancer-drug-company-as-advisor 2026-10-26 never 0.6 https://aktiv8.io/news/n6win13/cel-sci-presents-new-phase-3-multikine-data-at-world-congress-pre-surgical-biomarkers-iden 2026-10-26 never 0.6 https://aktiv8.io/news/n16mbysi/can-fite-presents-final-positive-data-from-phase-iia-pancreatic-cancer-study-of-namodenoso 2026-10-26 never 0.6 https://aktiv8.io/news/n14vrhvl/neoadjuvant-durvalumab-plus-chemotherapy-in-resectable-or-borderline-resectable-non-small- 2026-10-26 never 0.6 https://aktiv8.io/news/nnv1q96/obesity-biotech-corxel-is-going-public-in-a-merger-as-oral-glp-1-heads-to-phase-3-medcity- 2026-10-26 never 0.6 https://aktiv8.io/news/n3d6cs7/esmo-bristol-myers-cmo-touts-5-out-of-5-positive-phase-3-trials-for-bispecific-adc-iza-bre 2026-10-26 never 0.6 https://aktiv8.io/news/n1otgoah/heartbeam-s-heart-attack-assessment-technology-accepted-into-fda-s-total-product-life-cycl 2026-10-26 never 0.6 https://aktiv8.io/news/ndbm5qa/corcept-reports-positive-results-from-phase-2-bella-trial-of-lifyorli-combined-with-nab-pa 2026-10-26 never 0.6 https://aktiv8.io/news/na8lx7k/immuneering-presents-design-and-methodology-of-ongoing-phase-3-mapkeeper-301-trial-at-esmo 2026-10-26 never 0.6 https://aktiv8.io/news/n1uw8qyw/biontech-and-dualitybio-report-statistically-significant-but-modest-pfs-benefit-in-dynasty 2026-10-26 never 0.6 https://aktiv8.io/news/n1huzx54/cel-sci-presents-new-phase-3-multikine-data-at-world-congress-pre-surgical-biomarkers-iden 2026-10-26 never 0.6 https://aktiv8.io/news/n1f4u765/genmab-s-adc-beats-survival-expectations-in-phase-3-ovarian-cancer-trial-biospace 2026-10-26 never 0.6 https://aktiv8.io/news/n62d5fr/can-fite-presents-final-positive-data-from-phase-iia-pancreatic-cancer-study-of-namodenoso 2026-10-26 never 0.6 https://aktiv8.io/news/nhpvbwu/esmo-genmab-posts-phase-3-win-for-elahere-rival-ahead-of-very-interesting-data-from-merus- 2026-10-26 never 0.6 https://aktiv8.io/news/n1p9wpxt/biontech-sees-limited-benefit-to-adc-after-phase-3-reveals-modest-efficacy-ild-cases 2026-10-26 never 0.6 https://aktiv8.io/news/np74p6q/al-s-pharma-reports-new-ap-101-phase-2-weight-data-and-outlines-phase-3-clinical-trial-in- 2026-10-26 never 0.6 https://aktiv8.io/news/njv1kfj/treasury-to-limit-chinese-biotech-deals-but-still-allow-licensing-wsj 2026-10-26 never 0.6 https://aktiv8.io/news/neox8rk/ascletis-announces-fda-ind-submission-of-asc39-an-oral-small-molecule-selective-amylin-rec 2026-10-26 never 0.6 https://aktiv8.io/news/n1tlfk0l/biontech-and-dualitybio-announce-topline-results-of-global-phase-3-clinical-trial-for-brea 2026-10-26 never 0.6 https://aktiv8.io/news/n12fq24u/biontech-and-dualitybio-announce-topline-results-of-the-dynasty-breast02-global-phase-3-cl 2026-10-26 never 0.6 https://aktiv8.io/news/n1khwnp7/genmab-announces-updated-phase-2-data-demonstrating-more-than-two-year-median-overall-surv 2026-10-26 never 0.6 https://aktiv8.io/news/n10ikhh6/can-fite-presents-final-positive-data-from-phase-iia-pancreatic-cancer-study-of-namodenoso 2026-10-26 never 0.6 https://aktiv8.io/news/n1u77kj8/pluri-and-zeo-scientifix-partner-to-expand-u-s-manufacturing-and-commercial-platform-for-r 2026-10-26 never 0.6 https://aktiv8.io/news/ne1a8oh/serapha-bio-announces-positive-interim-safety-and-efficacy-data-from-the-serp-01-investiga 2026-10-26 never 0.6 https://aktiv8.io/news/namtxcj/lamassu-biotech-presents-initial-safety-and-pharmacokinetic-data-for-mdm2-inhibitor-sa53-f 2026-10-26 never 0.6 https://aktiv8.io/news/nrglz5q/immuneering-presents-design-and-methodology-of-ongoing-phase-3-mapkeeper-301-trial-at-esmo 2026-10-26 never 0.6 https://aktiv8.io/news/n1csje0x/genmab-announces-updated-phase-2-data-demonstrating-more-than-two-year-median-overall-surv 2026-10-26 never 0.6 https://aktiv8.io/news/n1nzytbz/ascletis-announces-fda-ind-submission-of-asc39-an-oral-small-molecule-selective-amylin-rec 2026-10-26 never 0.6 https://aktiv8.io/news/n1oq3qbk/mount-sinai-medical-center-physician-leads-global-phase-3-trial-showing-chemotherapy-free- 2026-10-26 never 0.6 https://aktiv8.io/news/n1zh5wb/humanetics-corporation-announces-fda-acceptance-of-investigational-new-drug-ind-applicatio 2026-10-26 never 0.6 https://aktiv8.io/news/n1t8oe2t/srx-global-announces-activation-of-the-university-of-california-davis-as-a-clinical-trial- 2026-10-26 never 0.6 https://aktiv8.io/news/n1s3pfxc/cero-therapeutics-announces-activation-of-additional-clinical-trial-site-for-the-certain-t 2026-10-26 never 0.6 https://aktiv8.io/news/n1rsvu60/pluri-and-zeo-scientifix-partner-to-expand-u-s-manufacturing-and-commercial-platform-for-r 2026-10-26 never 0.6 https://aktiv8.io/news/ngcc8ds/mount-sinai-medical-center-physician-leads-global-phase-3-trial-showing-chemotherapy-free- 2026-10-26 never 0.6 https://aktiv8.io/news/ngogu22/former-fda-head-steve-hahn-joins-breakbio-a-personalized-cancer-drug-company-as-advisor 2026-10-26 never 0.6 https://aktiv8.io/news/ngaojre/kos-biotechnology-partners-announces-strategic-investment-in-golden-age-health-to-accelera 2026-10-26 never 0.6 https://aktiv8.io/news/n1wukzfc/lamassu-biotech-presents-initial-safety-and-pharmacokinetic-data-for-mdm2-inhibitor-sa53-f 2026-10-26 never 0.6 https://aktiv8.io/news/n8rxrlc/tj-biopharma-doses-first-patient-in-phase-1-trial-of-tj-c64b-a-cldn6x4-1bb-bispecific-anti 2026-10-26 never 0.6 https://aktiv8.io/news/n1lzvvrz/eqs-news-al-s-pharma-reports-new-ap-101-phase-2-weight-data-and-outlines-phase-3-clinical- 2026-10-26 never 0.6 https://aktiv8.io/news/nh0lm3h/stocktwits-pharma-pulse-big-pharma-earnings-cancer-updates-and-2-fda-deadlines-the-week-s- 2026-10-26 never 0.6 https://aktiv8.io/news/n12tu2ko/nuvectis-reports-positive-data-from-nxp200-phase-1b-study-demonstrating-durable-responses- 2026-10-26 never 0.6 https://aktiv8.io/news/n1i79vcg/xilio-therapeutics-announces-first-patient-dosed-in-phase-1-2-clinical-trial-of-xtx501-in- 2026-10-26 never 0.6 https://aktiv8.io/news/n1sesrsy/tj-biopharma-doses-first-patient-in-phase-1-trial-of-tj-c64b-a-cldn6x4-1bb-bispecific-anti 2026-10-26 never 0.6 https://aktiv8.io/news/n6bthdt/former-fda-head-dr-stephen-hahn-joins-breakbio-a-personalized-cancer-drug-company-as-advis 2026-10-26 never 0.6 https://aktiv8.io/news/n78yu/ascletis-files-us-ind-for-oral-amylin-candidate-asc39-in-obesity-dealroom 2026-10-26 never 0.6 https://aktiv8.io/news/n4rzcyo/immuneering-presents-design-and-methodology-of-ongoing-phase-3-mapkeeper-301-trial-at-esmo 2026-10-26 never 0.6 https://aktiv8.io/news/n1e8rbvm/corcept-reports-positive-results-from-phase-2-bella-trial-of-lifyorli-combined-with-nab-pa 2026-10-26 never 0.6 https://aktiv8.io/news/n12muage/stocktwits-pharma-pulse-big-pharma-earnings-cancer-updates-and-2-fda-deadlines-the-week-s- 2026-10-26 never 0.6 https://aktiv8.io/news/n11y661t/cero-therapeutics-announces-activation-of-the-university-of-california-davis-as-a-clinical 2026-10-26 never 0.6 https://aktiv8.io/news/n2dp9lr/novartis-rhapsido-touts-solid-efficacy-with-industry-best-safety-data-in-rms-phase-3-revea 2026-10-26 never 0.6 https://aktiv8.io/news/n1qlm23w/can-fite-presents-final-positive-data-from-phase-iia-pancreatic-cancer-study-of-namodenoso 2026-10-26 never 0.6 https://aktiv8.io/news/nq3g7ou/equillium-announces-first-subject-dosed-in-phase-1-clinical-trial-of-eq504-eq-stock-news 2026-10-26 never 0.6 https://aktiv8.io/news/n1camwii/bristol-myers-squibb-and-systimmune-unveil-favorable-phase-3-results-in-lung-cancer-market 2026-10-26 never 0.6 https://aktiv8.io/news/nrp1z08/hutchmed-highlights-saffron-global-phase-iii-data-presented-at-esmo-congress-2026-and-simu 2026-10-26 never 0.6 https://aktiv8.io/news/np6559w/amanat-announces-377m-corxel-obesity-biotech-merger-grafa-com 2026-10-26 never 0.6 https://aktiv8.io/news/n1uokyyc/harbour-biomed-secures-china-s-nmpa-approval-for-batoclimab-expanding-treatment-options-fo 2026-10-26 never 0.6 https://aktiv8.io/news/nnqlt5z/rycarma-announces-first-patient-dosed-in-phase-2-clinical-trial-of-surlorian-for-the-treat 2026-10-26 never 0.6 https://aktiv8.io/news/n9vdipq/atom-therapeutics-announces-first-patient-dosed-in-phase-2-clinical-trial-of-lingdolinurad 2026-10-26 never 0.6 https://aktiv8.io/news/n1t6fz5/phase-3-emt2-trial-demonstrates-survival-benefit-for-high-dose-epa-news-medical 2026-10-26 never 0.6 https://aktiv8.io/news/nmn9wr1/esmo-roche-touts-convincing-phase-3-kras-data-after-win-over-rivals 2026-10-25 never 0.6 https://aktiv8.io/news/n1ijm6xf/esmo-astrazeneca-exec-insists-phase-3-adc-data-robust-enough-for-regulators-despite-pfs-mi 2026-10-25 never 0.6 https://aktiv8.io/news/nftgupy/2026-esmo-innovent-presented-phase-1-study-data-for-ibi3001-a-first-in-class-egfr-b7h3-bis 2026-10-25 never 0.6 https://aktiv8.io/news/nveozzn/esmo-bms-massacesi-hails-very-promising-data-for-biontech-partnered-pd-l1xvegf-a-drug 2026-10-25 never 0.6 https://aktiv8.io/news/n1t4rtks/biontech-bms-phase-2-lung-cancer-trial-shows-36-7-response-bntx-stock-news-stock-titan 2026-10-25 never 0.6 https://aktiv8.io/news/nxaesc2/2026-esmo-innovent-announcement-phase-2-data-presentation-for-ibi354-her2-adc-in-first-lin 2026-10-25 never 0.6 https://aktiv8.io/news/n1tv7qtz/xencor-presents-phase-1-dose-selection-data-for-xmab819-a-potential-first-in-class-enpp3-x 2026-10-25 never 0.6 https://aktiv8.io/news/n1spl5zs/personalized-melanoma-vaccine-improves-rfs-in-phase-3-trial-medscape 2026-10-25 never 0.6 https://aktiv8.io/news/nayzji9/biontech-and-bristol-myers-squibb-report-encouraging-phase-2-results-for-pumitamig-plus-do 2026-10-25 never 0.6 https://aktiv8.io/news/nks1sd9/china-s-pharma-licensing-deals-top-138-8-billion-with-150-9-billion-in-sight-this-year-big 2026-10-25 never 0.6 https://aktiv8.io/news/n13wipgk/genmab-announces-updated-follow-up-analyses-from-phase-2-study-of-petosemtamab-demonstrate 2026-10-25 never 0.6 https://aktiv8.io/news/n18w0m0t/xencor-presents-phase-1-dose-selection-data-for-xmab819-a-potential-first-in-class-enpp3-x 2026-10-25 never 0.6 https://aktiv8.io/news/n17dd2nu/biontech-and-bristol-myers-squibb-report-encouraging-global-phase-2-data-for-pumitamig-in- 2026-10-25 never 0.6 https://aktiv8.io/news/ntzej3e/2026-esmo-innovent-announcement-phase-2-data-presentation-for-ibi354-her2-adc-in-first-lin 2026-10-25 never 0.6 https://aktiv8.io/news/n1kb6dls/amarin-provides-update-on-university-of-leeds-sponsored-phase-3-epa-for-metastasis-trial-2 2026-10-25 never 0.6 https://aktiv8.io/news/n1r5n4ks/agenus-reports-72-of-patients-with-locally-advanced-dmmr-colon-cancer-had-no-cancer-remain 2026-10-25 never 0.6 https://aktiv8.io/news/nt2m1v1/biontech-and-bristol-myers-squibb-report-encouraging-global-phase-2-data-for-pumitamig-in- 2026-10-25 never 0.6 https://aktiv8.io/news/nhodet2/2026-esmo-innovent-presented-phase-1-study-data-for-ibi3001-a-first-in-class-egfr-b7h3-bis 2026-10-25 never 0.6 https://aktiv8.io/news/n69ms1u/2026-esmo-innovent-announcement-phase-2-data-presentation-for-ibi354-her2-adc-in-first-lin 2026-10-25 never 0.6 https://aktiv8.io/news/nrrq74q/genmab-announces-updated-follow-up-analyses-from-phase-2-study-of-petosemtamab-demonstrate 2026-10-25 never 0.6 https://aktiv8.io/news/n1qpl51o/ascletis-announces-fda-ind-submission-of-asc39-an-oral-small-molecule-selective-amylin-rec 2026-10-25 never 0.6 https://aktiv8.io/news/nwo0kxf/amarin-provides-update-on-university-of-leeds-sponsored-phase-3-epa-for-metastasis-trial-2 2026-10-25 never 0.6 https://aktiv8.io/news/n1nzsh11/stocktwits-pharma-pulse-big-pharma-earnings-cancer-updates-and-2-fda-deadlines-the-week-s- 2026-10-25 never 0.6 https://aktiv8.io/news/n1szbxum/arrivent-announces-initial-phase-1-data-for-cdh17-targeted-adc-arr-217-in-patients-with-ga 2026-10-25 never 0.6 https://aktiv8.io/news/n17o4e2n/agenus-reports-72-of-patients-with-locally-advanced-dmmr-colon-cancer-had-no-cancer-remain 2026-10-25 never 0.6 https://aktiv8.io/news/n16ol57j/biontech-and-bristol-myers-squibb-report-encouraging-global-phase-2-data-for-pumitamig-in- 2026-10-25 never 0.6 https://aktiv8.io/news/n13iwf1a/moderna-why-positive-phase-3-results-weren-t-enough-nasdaq-mrna 2026-10-24 never 0.6 https://aktiv8.io/news/ngkke3/genmab-and-incyte-announce-clinical-trial-collaboration-in-metastatic-colorectal-cancer 2026-10-24 never 0.6 https://aktiv8.io/news/np0a5ga/moderna-melanoma-therapy-cuts-recurrence-risk-42-in-phase-3-trial 2026-10-24 never 0.6 https://aktiv8.io/news/nnwd4zd/genmab-and-incyte-announce-clinical-trial-collaboration-in-metastatic-colorectal-cancer 2026-10-24 never 0.6 https://aktiv8.io/news/n1sbus49/orchid-pharma-licenses-antibiotic-to-libra-for-latin-america-investywise 2026-10-24 never 0.6 https://aktiv8.io/news/n14zbvb9/celcuity-presents-updated-results-from-the-pik3ca-mt-cohort-of-the-phase-3-viktoria-1-stud 2026-10-24 never 0.6 https://aktiv8.io/news/n1tgx1sg/celcuity-presents-updated-results-from-the-pik3ca-mt-cohort-of-the-phase-3-viktoria-1-stud 2026-10-24 never 0.6 https://aktiv8.io/news/n17n74qy/compass-therapeutics-announces-publication-of-phase-2-3-companion-002-results-for-tovecimi 2026-10-24 never 0.6 https://aktiv8.io/news/n2vsi26/upacicalcet-meets-primary-endpoints-in-phase-3-trials-for-secondary-hyperparathyroidism-th 2026-10-24 never 0.6 https://aktiv8.io/news/n9dpl3z/parabilis-medicines-presents-updated-phase-1-2-data-for-zolucatetide-demonstrating-compell 2026-10-24 never 0.6 https://aktiv8.io/news/nib39j3/climb-bio-presents-initial-prismn-phase-2-data-from-budoprutug-in-pmn-at-an-oral-session-a 2026-10-24 never 0.6 https://aktiv8.io/news/n19mw8ct/incyte-and-genmab-announce-clinical-trial-collaboration-in-metastatic-colorectal-cancer-gm 2026-10-24 never 0.6 https://aktiv8.io/news/naikiv6/personalized-mrna-melanoma-vaccine-cut-recurrence-or-death-risk-42-in-phase-3-trial-but-su 2026-10-24 never 0.6 https://aktiv8.io/news/neqq4yp/amgen-amgn-reports-positive-phase-3-tezspire-results-in-eosinophilic-esophagitis 2026-10-24 never 0.6 https://aktiv8.io/news/nx0y9il/nanobiotix-announces-final-data-from-phase-1-study-evaluating-jnj-1900-nbtxr3-with-immune- 2026-10-24 never 0.6 https://aktiv8.io/news/n10j3702/pfizer-s-25-valent-pediatric-pneumococcal-conjugate-vaccine-candidate-shows-robust-phase-2 2026-10-24 never 0.6 https://aktiv8.io/news/na4wu0e/celcuity-presents-updated-results-from-the-pik3ca-mt-cohort-of-the-phase-3-viktoria-1-stud 2026-10-24 never 0.6 https://aktiv8.io/news/nsj42ew/zymeworks-presents-new-phase-1-data-for-folate-receptor-alpha-targeting-antibody-drug-conj 2026-10-24 never 0.6 https://aktiv8.io/news/nk97xh8/climb-bio-presents-initial-prismn-phase-2-data-from-budoprutug-in-pmn-at-an-oral-session-a 2026-10-24 never 0.6 https://aktiv8.io/news/n12g8zta/junshi-biosciences-announces-completion-of-first-patient-dosing-in-the-phase-3-clinical-tr 2026-10-24 never 0.6 https://aktiv8.io/news/n1sxsbe7/parabilis-medicines-presents-updated-phase-1-2-data-for-zolucatetide-demonstrating-compell 2026-10-24 never 0.6 https://aktiv8.io/news/n1b7jxbq/pfizer-s-25-valent-pediatric-pneumococcal-conjugate-vaccine-candidate-shows-robust-phase-2 2026-10-24 never 0.6 https://aktiv8.io/news/nyq1t0u/catalym-presents-phase-2-data-showing-visugromab-substantially-enhances-the-clinical-benef 2026-10-24 never 0.6 https://aktiv8.io/news/nfywkrw/esmo-astrazeneca-exec-insists-phase-3-adc-data-robust-enough-for-regulators-despite-pfs-mi 2026-10-24 never 0.6 https://aktiv8.io/news/n1k25fpe/esmo-roche-touts-convincing-phase-3-kras-data-after-win-over-rivals 2026-10-24 never 0.6 https://aktiv8.io/news/n1az8wfy/esmo-genmab-posts-phase-3-win-for-elahere-rival-ahead-of-very-interesting-data-from-merus- 2026-10-24 never 0.6 https://aktiv8.io/news/n1jqv7jj/incyte-and-genmab-announce-clinical-trial-collaboration-in-metastatic-colorectal-cancer 2026-10-24 never 0.6 https://aktiv8.io/news/njh5mdu/nanobiotix-announces-final-data-from-phase-1-study-evaluating-jnj-1900-nbtxr3-with-immune- 2026-10-24 never 0.6 https://aktiv8.io/news/n86xbz0/brenus-pharma-s-novel-in-vivo-immunotherapy-stc-1010-shows-safety-activating-t-cells-in-fi 2026-10-23 never 0.6 https://aktiv8.io/news/nzjma2y/oric-pharmaceuticals-reports-best-in-class-enozertinib-data-in-first-line-egfr-atypical-ns 2026-10-23 never 0.6 https://aktiv8.io/news/n1wcdals/genmab-stock-surges-9-following-positive-phase-3-ovarian-cancer-trial-results-investing-co 2026-10-23 never 0.6 https://aktiv8.io/news/nzetivo/tango-therapeutics-reports-82-objective-response-rate-for-vopimetostat-plus-daraxonrasib-i 2026-10-23 never 0.6 https://aktiv8.io/news/nhb9ol4/novo-s-awiqli-receives-fda-approval-as-the-first-and-only-once-weekly-insulin-for-children 2026-10-23 never 0.6 https://aktiv8.io/news/n1rq8ewa/palleon-pharmaceuticals-presents-phase-2-results-for-hlx79-e-602-in-primary-membranous-nep 2026-10-23 never 0.6 https://aktiv8.io/news/n2afdyz/u-s-fda-approves-subcutaneous-induction-regimen-for-abbvie-s-skyrizi-risankizumab-rzaa-for 2026-10-23 never 0.6 https://aktiv8.io/news/nmg4kd/novo-s-awiqli-receives-fda-approval-as-the-first-and-only-once-weekly-insulin-for-children 2026-10-23 never 0.6 https://aktiv8.io/news/n1ddizt4/u-s-fda-approves-subcutaneous-induction-regimen-for-abbvie-s-skyrizi-risankizumab-rzaa-for 2026-10-23 never 0.6 https://aktiv8.io/news/nj8dgs7/pathalys-pharma-presents-positive-data-from-pivotal-phase-3-studies-of-upacicalcet-in-feat 2026-10-23 never 0.6 https://aktiv8.io/news/n16beuux/ide849-shr-4849-dll3-top1-adc-updated-phase-1-results-at-esmo-2026-demonstrates-promising- 2026-10-23 never 0.6 https://aktiv8.io/news/n18l3dmn/biotech-stock-bolt-biotherapeutics-nasdaq-bolt-soars-on-acquisition-news-investorideas-com 2026-10-23 never 0.6 https://aktiv8.io/news/n1ubxcdm/alnylam-announces-positive-initial-phase-1b-data-for-brezosiran-aln-htt02-demonstrating-de 2026-10-23 never 0.6 https://aktiv8.io/news/n61wate/roche-puts-numbers-behind-phase-3-kidney-disease-win-amid-blockbuster-ambitions 2026-10-23 never 0.6 https://aktiv8.io/news/n195c2ne/ascletis-strategic-partner-sagimet-announces-first-patient-dosed-in-phase-iii-u-s-clinical 2026-10-23 never 0.6 https://aktiv8.io/news/n1nplunl/santhera-s-licensing-partner-nxera-pharma-submits-marketing-authorization-application-for- 2026-10-23 never 0.6 https://aktiv8.io/news/n1njpdyp/evaxion-announces-89-vaccine-target-precision-and-sustained-t-cell-and-clinical-responses- 2026-10-23 never 0.6 https://aktiv8.io/news/n1e36lpc/impact-biotech-reports-encouraging-early-clinical-results-from-phase-1-study-of-padeliporf 2026-10-23 never 0.6 https://aktiv8.io/news/n1bax6hq/harbour-biomed-receives-china-nmpa-approval-of-batoclimab-injection-subcutaneous-injection 2026-10-23 never 0.6 https://aktiv8.io/news/n1txbw18/gondolabio-and-children-s-tumor-foundation-announce-partnership-to-advance-gondolabio-s-ne 2026-10-23 never 0.6 https://aktiv8.io/news/nmiqzin/arrivent-to-present-initial-phase-1-data-for-cdh17-targeted-adc-arr-217-in-patients-with-g 2026-10-23 never 0.6 https://aktiv8.io/news/n1cslpf4/biolinerx-and-hemispherian-present-preclinical-data-demonstrating-synergy-of-glix1-with-pa 2026-10-23 never 0.6 https://aktiv8.io/news/ntmobag/ionis-partner-roche-announces-new-phase-3-data-showing-sefaxersen-significantly-reduced-pr 2026-10-23 never 0.6 https://aktiv8.io/news/n5rie60/tg-therapeutics-announces-phase-1-data-evaluating-azer-cel-in-progressive-multiple-scleros 2026-10-23 never 0.6 https://aktiv8.io/news/n1vwsr2a/alebund-pharmaceuticals-announces-poster-presentation-by-partner-r1-therapeutics-of-global 2026-10-23 never 0.6 https://aktiv8.io/news/nnc63dz/2026-esmo-lba-innovent-announces-international-phase-3-study-of-arcotatug-tavatecan-cldn18 2026-10-23 never 0.6 https://aktiv8.io/news/n2xkmbm/marengo-therapeutics-presents-phase-2-start-001-results-at-esmo-2026-demonstrating-tissue- 2026-10-23 never 0.6 https://aktiv8.io/news/n1glto0a/esmo-2026-tango-trips-on-sinking-response-rates-in-pancreatic-cancer-but-will-move-to-phas 2026-10-23 never 0.6 https://aktiv8.io/news/n19v1hkg/2026-esmo-lba-innovent-announces-international-phase-3-study-of-arcotatug-tavatecan-cldn18 2026-10-23 never 0.6 https://aktiv8.io/news/nm1emru/esmo-takeda-s-1-2b-bet-on-innovent-absolutely-pays-off-with-details-of-adc-s-phase-3-win 2026-10-23 never 0.6 https://aktiv8.io/news/nkr6c0m/pathos-ai-announces-strategic-collaborations-with-bristol-myers-squibb-and-tempus-ai-to-ad 2026-10-23 never 0.6 https://aktiv8.io/news/n1s6i36r/evaxion-announces-89-vaccine-target-precision-and-sustained-t-cell-and-clinical-responses- 2026-10-23 never 0.6 https://aktiv8.io/news/n1gmjaa8/pathalys-pharma-presents-positive-data-from-pivotal-phase-3-studies-of-upacicalcet-in-feat 2026-10-23 never 0.6 https://aktiv8.io/news/n1adb07k/alnylam-announces-positive-initial-phase-1b-data-for-brezosiran-aln-htt02-demonstrating-de 2026-10-23 never 0.6 https://aktiv8.io/news/n8jrtpw/biolinerx-and-hemispherian-present-preclinical-data-demonstrating-synergy-of-glix1-with-pa 2026-10-23 never 0.6 https://aktiv8.io/news/neyl7sa/breakthrough-vaccine-for-the-deadliest-skin-cancer-cut-risk-by-almost-half-the-washington- 2026-10-23 never 0.6 https://aktiv8.io/news/nkxjayr/roivant-soars-8-as-brepocitinib-delivers-phenomenal-results-in-two-phase-3-uveitis-trials 2026-10-23 never 0.6 https://aktiv8.io/news/n1hbfkp2/ide849-shr-4849-dll3-top1-adc-updated-phase-1-results-at-esmo-2026-demonstrates-promising- 2026-10-23 never 0.6 https://aktiv8.io/news/n6sgg1c/tango-presents-promising-results-from-phase-1-2-study-of-vopimetostat-and-daraxonrasib-in- 2026-10-23 never 0.6 https://aktiv8.io/news/n1h0vzgt/ascletis-strategic-partner-sagimet-announces-first-patient-dosed-in-phase-iii-u-s-clinical 2026-10-23 never 0.6 https://aktiv8.io/news/n1qy9ksq/takeda-announces-arcotatug-tavatecan-tak-921-demonstrated-statistically-significant-and-cl 2026-10-23 never 0.6 https://aktiv8.io/news/n1lt2bba/merck-moderna-s-melanoma-combination-therapy-delivers-promising-phase-3-trial-results 2026-10-23 never 0.6 https://aktiv8.io/news/n1qzrnlp/oric-pharmaceuticals-presents-potential-best-in-class-data-for-enozertinib-in-1l-nsclc-pat 2026-10-23 never 0.6 https://aktiv8.io/news/n1hjh4xs/roche-puts-numbers-behind-phase-3-kidney-disease-win-amid-blockbuster-ambitions 2026-10-23 never 0.6 https://aktiv8.io/news/n860iv4/certified-fisetin-vs-uncertified-why-hygieia-s-fssc-22000-fda-registered-standards-guarant 2026-10-23 never 0.6 https://aktiv8.io/news/n1ac1xpe/macrogenics-announces-positive-interim-phase-1-results-for-mgc026-and-highlights-plans-to- 2026-10-23 never 0.6 https://aktiv8.io/news/n14bul42/perspective-s-212pb-bamzireotide-navoxetan-vmt-net-demonstrates-encouraging-safety-durable 2026-10-23 never 0.6 https://aktiv8.io/news/nosevdl/marengo-therapeutics-presents-phase-2-start-001-results-at-esmo-2026-demonstrating-tissue- 2026-10-23 never 0.6 https://aktiv8.io/news/ny7i8a2/zymeworks-licenses-experimental-lung-cancer-drug-to-roche-in-up-to-813-million-deal-global 2026-10-23 never 0.6 https://aktiv8.io/news/n1pjlxq2/waters-and-labcorp-to-expand-access-to-cervical-cancer-screening-with-the-most-comprehensi 2026-10-23 never 0.6 https://aktiv8.io/news/ng47axz/actinium-pharmaceuticals-to-highlight-first-in-human-phase-1-study-of-atnm-400-a-her3-targ 2026-10-23 never 0.6 https://aktiv8.io/news/n1m7y42k/elicio-therapeutics-presents-late-breaking-phase-2-amplify-7p-results-at-esmo-congress-202 2026-10-23 never 0.6 https://aktiv8.io/news/nqzf1pu/zymeworks-licenses-experimental-lung-cancer-drug-to-roche-in-up-to-813-million-deal-the-mi 2026-10-23 never 0.6 https://aktiv8.io/news/ng3buwq/advancell-presents-updated-phase-1-results-on-advc001-at-esmo-2026-with-encouraging-long-t 2026-10-23 never 0.6 https://aktiv8.io/news/n1ix2tt9/alebund-pharmaceuticals-announces-poster-presentation-by-partner-r1-therapeutics-of-global 2026-10-23 never 0.6 https://aktiv8.io/news/n1wlilm0/streamlining-global-supply-redfy-advances-high-quality-red-light-therapy-mask-wholesale-un 2026-10-23 never 0.6 https://aktiv8.io/news/n7yxdvk/will-washington-regulate-biotech-licensing-like-semiconductors-tracking-binsa-and-treasury 2026-10-23 never 0.6 https://aktiv8.io/news/n1aamlly/full-life-technologies-reports-encouraging-preliminary-phase-1-safety-and-psa-decline-for- 2026-10-23 never 0.6 https://aktiv8.io/news/nn4ofd9/immunoforge-to-showcase-proprietary-platform-technologies-and-next-generation-oncology-pha 2026-10-23 never 0.6 https://aktiv8.io/news/n14ru33k/coreline-soft-receives-u-s-fda-510-k-clearance-for-aview-aorta-metrics-expanding-its-chest 2026-10-23 never 0.6 https://aktiv8.io/news/n1iv21t2/2026-esmo-lba-innovent-announces-international-phase-3-study-of-arcotatug-tavatecan-cldn18 2026-10-23 never 0.6 https://aktiv8.io/news/n1ob9h9o/ide849-shr-4849-dll3-top1-adc-updated-phase-1-results-at-esmo-2026-demonstrates-promising- 2026-10-23 never 0.6 https://aktiv8.io/news/n17xltm2/pasithea-therapeutics-announces-positive-pas-004-clinical-data-from-phase-1-advanced-cance 2026-10-23 never 0.6 https://aktiv8.io/news/ndg5zcz/pentara-to-present-rare-disease-statistical-innovations-at-nord-summit-aligning-with-fda-s 2026-10-23 never 0.6 https://aktiv8.io/news/npnu6o1/stat-novartis-multiple-sclerosis-treatment-cuts-rates-of-relapse-in-pivotal-trials 2026-10-23 never 0.6 https://aktiv8.io/news/n1s4qq6w/stat-most-cancer-drugs-approved-by-european-regulators-lack-a-high-clinical-benefit-analys 2026-10-23 never 0.6 https://aktiv8.io/news/nvamm88/full-life-technologies-reports-encouraging-preliminary-phase-1-safety-and-psa-decline-for- 2026-10-23 never 0.6 https://aktiv8.io/news/nh6yjk6/bristol-myers-squibb-presents-results-from-phase-1-breakfree-2-study-of-zolacabtagene-auto 2026-10-23 never 0.6 https://aktiv8.io/news/nqpyco8/aeon-biopharma-outlines-abp-450-biosimilar-plan-targets-q4-2026-ind-tradingview 2026-10-23 never 0.6 https://aktiv8.io/news/n1rnm20y/abbvie-announces-topline-results-from-the-phase-3-intrepid-trial-showing-lutikizumab-signi 2026-10-22 never 0.6 https://aktiv8.io/news/n5t5tv/merck-and-moderna-will-present-results-from-landmark-phase-3-interpath-001-trial-for-intis 2026-10-22 never 0.6 https://aktiv8.io/news/ns423jb/abbvie-s-skin-disease-drug-hits-phase-3-goal-but-efficacy-falls-short-of-benchmarks-analys 2026-10-22 never 0.6 https://aktiv8.io/news/n18bbcvw/biontech-advances-phase-3-clinical-trial-of-pumitamig-in-combination-with-gilead-s-trop2-d 2026-10-22 never 0.6 https://aktiv8.io/news/nf2xycj/scisparc-subsidiary-neurothera-labs-reports-positive-progress-in-fda-approved-phase-iib-cl 2026-10-22 never 0.6 https://aktiv8.io/news/n4rtz5u/telitacicept-demonstrates-durable-preservation-of-kidney-function-through-two-years-in-pha 2026-10-22 never 0.6 https://aktiv8.io/news/n1ukafhh/ecosave-named-entitlement-partner-of-dover-motor-speedway-s-2027-nascar-cup-series-race 2026-10-22 never 0.6 https://aktiv8.io/news/nkqdshc/arbutus-announces-fda-clinical-hold-is-lifted-on-ind-application-for-ab-101-an-oral-pd-l1- 2026-10-22 never 0.6 https://aktiv8.io/news/n1ocxhjb/sagimet-biosciences-announces-first-patient-dosed-in-aurora-phase-3-u-s-clinical-trial-of- 2026-10-22 never 0.6